Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)

Phase 1

Recruiting

Conditions: Muscular Atrophy, Spinal

Interventions: Drug: Nusinersen
Device: ThecaFlex DRx System

First Posted Date: 2024-08-15

Last Posted Date: 2025-02-07

Lead Sponsor: Biogen

Target Recruit Count: 55

Registration Number: NCT06555419

Locations: 🇺🇸
Texas Childrens Hospital Houston, Houston, Texas, United States

A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled BIIB080 Co-administered With BIIB080 in Healthy Adults

Phase 1

Recruiting

Conditions: Healthy Volunteer

Interventions: Drug: [89Zr]Zr-DFO-BIIB080
Drug: BIIB080

First Posted Date: 2024-06-12

Last Posted Date: 2025-03-17

Lead Sponsor: Biogen

Target Recruit Count: 5

Registration Number: NCT06454721

Locations: 🇺🇸
UC Davis, Sacramento, California, United States

A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: [14C]-BIIB091

First Posted Date: 2024-03-15

Last Posted Date: 2024-05-23

Lead Sponsor: Biogen

Target Recruit Count: 8

Registration Number: NCT06311786

Locations: 🇺🇸
PPD Clinical Research Unit, Austin, Texas, United States

A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: BIIB122
Drug: Rabeprazole

First Posted Date: 2024-02-20

Last Posted Date: 2024-07-19

Lead Sponsor: Biogen

Target Recruit Count: 18

Registration Number: NCT06264440

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: BIIB800
Drug: Actemra

First Posted Date: 2024-02-16

Last Posted Date: 2024-12-24

Lead Sponsor: Biogen

Target Recruit Count: 300

Registration Number: NCT06262477

Locations: 🇬🇧
Fortrea Clinical Research Unit Inc., Leeds, West Yorkshire, United Kingdom

A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

First Posted Date: 2023-11-13

Last Posted Date: 2024-12-18

Lead Sponsor: Biogen

Target Recruit Count: 474

Registration Number: NCT06127095

Locations: 🇺🇸
Biogen, Cambridge, Massachusetts, United States

A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

Phase 1

Recruiting

Conditions: Lupus Nephritis

Interventions: Drug: Felzartamab

First Posted Date: 2023-10-03

Last Posted Date: 2025-05-14

Lead Sponsor: HI-Bio, A Biogen Company

Target Recruit Count: 20

Registration Number: NCT06064929

Locations: 🇺🇸
R & H Clinical Research, Katy, Texas, United States
🇺🇸
Centricity Research - Phoenix, Mesa, Arizona, United States
🇺🇸
University of California, San Diego (UCSD), La Jolla, California, United States

and more 24 locations

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

Phase 1

Recruiting

Conditions: Friedreich Ataxia

Interventions: Drug: Omaveloxolone

First Posted Date: 2023-09-26

Last Posted Date: 2025-05-21

Lead Sponsor: Biogen

Target Recruit Count: 35

Registration Number: NCT06054893

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (LTE AMETHYST)

Phase 3

Conditions: Chronic Cutaneous Lupus Erythematosus
Subacute Cutaneous Lupus Erythematosus

Interventions: Drug: BIIB059 (litifilimab)

First Posted Date: 2023-09-21

Last Posted Date: 2025-04-22

Lead Sponsor: Biogen

Target Recruit Count: 322

Registration Number: NCT06044337

Locations: 🇺🇸
Revival Research Institute, LLC, Troy, Michigan, United States
🇮🇹
Università degli studi di Firenze, Firenze, Italy
🇺🇸
David Fivenson, MD, Dermatology, PLLC, Ann Arbor, Michigan, United States

and more 48 locations

A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers

Phase 1

Completed

Conditions: Autoimmunity
Immune System Diseases

Interventions: Drug: Placebo
Drug: HIB210

First Posted Date: 2023-07-03

Last Posted Date: 2025-02-07

Lead Sponsor: HI-Bio, A Biogen Company

Target Recruit Count: 30

Registration Number: NCT05928585

Locations: 🇺🇸
HI-Bio Investigational Site, Hialeah, Florida, United States

Home Terms & Conditions Privacy Policy